MX9700413A - Inhibidores de proteina fijadora de factor liberador de corticotropina y su uso. - Google Patents

Inhibidores de proteina fijadora de factor liberador de corticotropina y su uso.

Info

Publication number
MX9700413A
MX9700413A MX9700413A MX9700413A MX9700413A MX 9700413 A MX9700413 A MX 9700413A MX 9700413 A MX9700413 A MX 9700413A MX 9700413 A MX9700413 A MX 9700413A MX 9700413 A MX9700413 A MX 9700413A
Authority
MX
Mexico
Prior art keywords
crf
ligand inhibitor
corticotropin
administration
releasing factor
Prior art date
Application number
MX9700413A
Other languages
English (en)
Inventor
Dominic P Behan
Phillip J Lowry
Wylie W Vale Jr
Stephen C Heinrichs
Steven W Sutton
Jean E F Rivier
Errol Desouza
Original Assignee
Neurocrine Biosciences Inc
Salk Inst
Univ Reading
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurocrine Biosciences Inc, Salk Inst, Univ Reading filed Critical Neurocrine Biosciences Inc
Priority claimed from PCT/US1995/008867 external-priority patent/WO1996002569A1/en
Publication of MX9700413A publication Critical patent/MX9700413A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/57509Corticotropin releasing factor [CRF] (Urotensin)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se incrementan los niveles de factor liberador de corticotropina libre (CRF) en el cerebro, mediante la administracion CRF/proteína fijadora de CRF, provocando la liberacion de CRF. El inhibidor de ligando puede ser un péptido derivado a partir de CRF, o una proteína relacionada, o un no péptido. La administracion del inhibidor de ligando puede proporcionar una mejora en el aprendizaje y la memoria, dando como resultado una ingestion de alimento disminuida, o proporcionar un tratamiento para enfermedades asociadas con bajos niveles de CRF en el cerebro, notablemente la enfermedad de Alzheimer. También se proporciona un método para rastrear compuestos para seleccionar antagonistas de CRF particularmente efectivos para su administracion en vivo a mamíferos.
MX9700413A 1994-07-15 1995-07-14 Inhibidores de proteina fijadora de factor liberador de corticotropina y su uso. MX9700413A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US27624094A 1994-07-15 1994-07-15
US48477695A 1995-06-07 1995-06-07
PCT/US1995/008867 WO1996002569A1 (en) 1994-07-15 1995-07-14 Corticotropin-releasing factor-binding-protein inhibitors and their use

Publications (1)

Publication Number Publication Date
MX9700413A true MX9700413A (es) 1998-05-31

Family

ID=26957870

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9700413A MX9700413A (es) 1994-07-15 1995-07-14 Inhibidores de proteina fijadora de factor liberador de corticotropina y su uso.

Country Status (7)

Country Link
EP (1) EP0771323A1 (es)
JP (2) JPH10503187A (es)
CN (1) CN1157620A (es)
AU (1) AU705984B2 (es)
CA (1) CA2195197A1 (es)
MX (1) MX9700413A (es)
NO (1) NO970165L (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107058237A (zh) * 2016-12-07 2017-08-18 陈锋 杂交瘤细胞株及基于杂交瘤细胞株的抗crh抗体c‑d17及其检测方面的应用
CN107043752A (zh) * 2016-12-07 2017-08-15 陈锋 杂交瘤细胞株及基于杂交瘤细胞株的抗crh抗体n‑d19及其检测方面的应用
KR20230043222A (ko) * 2020-08-12 2023-03-30 스프루스 바이오사이언시스 인코포레이티드 다낭성 난소 증후군을 치료하기 위한 방법 및 조성물

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4908352A (en) * 1987-09-28 1990-03-13 The Salk Institute For Biological Studies Urotensin peptides
US5464757A (en) * 1991-01-15 1995-11-07 The Salk Institute For Biological Studies DNA encoding CRF binding protein

Also Published As

Publication number Publication date
JPH10503187A (ja) 1998-03-24
JP2001348400A (ja) 2001-12-18
CA2195197A1 (en) 1996-02-01
AU705984B2 (en) 1999-06-03
NO970165D0 (no) 1997-01-14
CN1157620A (zh) 1997-08-20
AU3128395A (en) 1996-02-16
NO970165L (no) 1997-03-14
EP0771323A1 (en) 1997-05-07

Similar Documents

Publication Publication Date Title
NZ504026A (en) Methods for treating hypercoagulable states or acquired protein C deficiency using human-activated protein C
ATE266417T1 (de) Medikamente zur vorbeugung oder behandlung von vaskulären hämorrhagien
DE69625691D1 (de) Verabreichung von peptidylheterocyclen zur behandlung von thrombin in zusammenhang stehenden krankheiten
ES2170104T3 (es) Inhibidores de la produccion de proteinas de beta-amiloide.
DE69630479D1 (de) Arzneimittel zur Behandlung von entzündlichen Herzkrankheiten
DE59711321D1 (de) Neue substituierte pyrazolderivate zur behandlung von herzkreislauferkrankungen
DE69626539D1 (de) topische Verwendung von Vitamin D zur Behandlung von Augenerkrankungen
DE69521796D1 (de) Behandlung des partiellen wachstumshormon-unempfindlichkeitssyndromes
DE69822665D1 (de) Verwendung von 9-desoxy-2',9-alpha-methano-3-oxa-4,5,6-trinor-3,7-(1',3'-interphenylen)-13,14-dihydroprostaglandin-f1 zur behandlung von peripheren vaskulären erkrankungen
DE69636343D1 (de) Verwendung von glu-trp dipeptiden zur herstellung eines arzneimittels zur behandlung von verschiedenen gefässneubildung-assozierten erkrankungen
MY102806A (en) Human interleukin-3 and muteins thereof
DE69631478D1 (de) Verwendung von vitamin d4-derivaten zur behandlung von hauterkrankungen
DE69614375T2 (de) Dermatologische zubereitung zur behandlung von aktinischen keratosen
ATE201992T1 (de) Carbostyrilderivat zur behandlung von ophthalmologischen erkrankungen
GEP20053423B (en) Method of Inhibiting Amyloid Protein Aggregation and Method for Imaging of Amyloid Deposits
DE69201660T2 (de) Verwendung von Acetyl L-Carnitin zur therapeutischen Behandlung von Coma.
MX9700413A (es) Inhibidores de proteina fijadora de factor liberador de corticotropina y su uso.
DE69533311D1 (de) Verfahren zur behandlung von autoimmunerkrankungen mittels typ-1-interferonen
DE69822297D1 (de) Triptolid-derivate geeignet zur behandlung von autoimmunkrankheiten
GR3034035T3 (en) A process for the preparation of factor ix from biological sources
DE69837271D1 (de) Mutanten des thyroid-stimulierenden hormons
KR950016720A (ko) 아밀로이드 단백질의 효과를 저해하는 방법
DE69213660D1 (de) Verwendung von 1-(beta-d-arabinofuranosyl)-5-propynyluracil zur senkung des serumcholesterins
ATE249837T1 (de) Caspase 8-inhibitoren zur immunsuppression
DE69930419D1 (de) Verwendung von menschliche protein c zur herstellung eines arzneimittels zur behandlung von heparininduzierter thrombozytopenie